Association of Capecitabine Pharmacokinetics and Toxicity With Aging
2018년 3월 7일 업데이트: Newcastle-upon-Tyne Hospitals NHS Trust
A Prospective Evaluation of Capecitabine and Metabolite Pharmacokinetics in Elderly Breast and Colorectal Cancer Patients and Their Association With Toxicity and Molecular Markers of Enzyme Activity and Aging
This is a multi-centre prospective non-interventional study designed to evaluate the effects of patient age on the pharmacokinetics of capecitabine and its metabolites 5'DFCR, 5'DFUR, and 5-FU.
In addition, the study will assess the correlation between the pharmacokinetic parameters calculated and cytidine deaminase, biomarkers of aging, clinical frailty, treatment outcome, and toxicity.
To be enrolled, patients must have breast or colorectal cancer and be eligible to receive capecitabine monotherapy in accordance with its approved clinical usage in the UK.
Treatment will be administered according to NICE guidelines as well as the clinical judgement of the prescribing physician.
One hundred patients (50 breast cancer patients, 50 colorectal cancer patients) who are about to start treatment with capecitabine monotherapy will be recruited to the study and undergo study procedures within the first week of treatment.
연구 개요
상태
상태
알려지지 않은
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
중재적
등록 (예상)
등록
100
단계
단계
- 4단계
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
1) Histologic or cytologic diagnosis of breast cancer or colorectal cancer. Patients should have disease that is suitable for capecitabine monotherapy as defined by the NICE Guidelines.
2) Patients must be within the first week of their first cycle of capecitabine treatment.
3) Estimated life expectancy of greater than 3 months. 4) Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. 5) Total serum bilirubin less than or equal to 25 micromol/L. 6) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels less than 2.5 times the upper limit of the normal range.
7) Serum albumin level greater than 32 g/L. 8) Creatinine clearance greater than or equal to 30 mL/minute. 9) Blood haemoglobin level of greater than 9 g/dL, with transfusion allowed. 10) Absolute neutrophil count greater than 2.5 x 109/L. 11) Platelet count greater than 100 x 109/L. 12) 18 years of age or older. 13) Written informed consent.
Exclusion Criteria:
- Pregnancy or breast feeding.
- Known HIV, Hepatitis B, or Hepatitis C infection.
- Known Gilbert syndrome.
- Uncontrolled diabetes (HbA1c greater than 7.5%).
Any condition or disease that might affect oral absorption of medications, including:
- Crohn's disease
- Ulcerative colitis
Major gastric or small bowel resection
-
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
1
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: 카페시타빈
|
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Area under the curve (AUC) of capecitabine and metabolites
기간: 0 (pre-dose), 0.5, 1, 2, 4, and 6 hours post dose
|
Measurement of AUC of capecitabine and its metabolites 5'deoxy-5-fluorocytidine (5'DFCR), 5'deoxy-5-fluorouridine (5'DFUR), and 5-fluorouracil.
|
0 (pre-dose), 0.5, 1, 2, 4, and 6 hours post dose
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Toxicities and grades as scaled by Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.03
기간: Six months
|
Toxicity grade(s) as measured by CTCAE version 4.03 (published by the U.S. Department of Heath and Human Services 2009).
General grading scheme is as follows: Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL).
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.
Grade 4: Life-threatening consequences; urgent intervention indicated.
Grade 5: Death related to AE.
|
Six months
|
|
Progression free survival as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1
기간: From time of enrollment until first documented progression
|
Progression free survival as measured by the RECIST criteria version 1.1 (Eisenhauer et al., 2009).
The RECIST criteria define progression as 'at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Note: the appearance of one or more new lesions is also considered progression)'
|
From time of enrollment until first documented progression
|
|
Response as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1
기간: From time of enrollment to first documented response
|
Complete or partial response as measured by the RECIST criteria version 1.1. (Eisenhauer et al., 2009) Complete response = 'Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial response = 'At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.' |
From time of enrollment to first documented response
|
|
Grip strength measured in kg
기간: During 6-hour pharmacokinetic study session
|
Grip strength measured in kg by the grip strength test (using the Takei handheld dynamometer)
|
During 6-hour pharmacokinetic study session
|
|
Frailty as measured by the Edmonton Frail Scale
기간: During 6-hour pharmacokinetic study session
|
Frailty as measured by the Edmonton Frail Scale.
A 17 point scale that measures 9 frailty domains.
0-5: not frail; 6-7: vulnerable; 8-9: mild frailty; 10-11: moderate frailty; 12-17: severe frailty.
|
During 6-hour pharmacokinetic study session
|
|
Nutritional status as measured by the Mini Nutritional Assessment questionnaire
기간: During 6-hour pharmacokinetic study session
|
Nutritional status as measured by the Mini Nutritional Assessment questionnaire, a 30 point test on nutritional status. Scoring: 24 to 30 points: Normal nutritional status. 17 to 23.5 points: At risk of malnutrition. Less than 17 points: malnourished. |
During 6-hour pharmacokinetic study session
|
|
Quality of life as assessed by the European Organization for Research and Treatment of Cancer quality of life (EORTC-QLQ-C30 version 3) questionnaire
기간: During 6-hour pharmacokinetic study session
|
Quality of life as measured by the EORTC-QLQ-C30 version 3 questionnaire.
This questionnaire assesses the quality of life of cancer patients in a series of 30 questions, with 28 of the questions on a scale of 1 to 4 where 1 is 'not at all' and 4 is 'very much'.
Final two questions relate to overall quality of life and health on a scale of 1 to 7, where 1 is 'very poor' and 7 is 'excellent'.
|
During 6-hour pharmacokinetic study session
|
|
Plasma cytidine deaminase activity (measured in units/mg protein by spectrophotometric assay)
기간: 0 hours post dose (pre-dose)
|
Plasma cytidine deaminase activity (measured in units/mg protein by spectrophotometric assay).
|
0 hours post dose (pre-dose)
|
|
Maximum plasma concentration (Cmax) of capecitabine and metabolites
기간: 0 (pre-dose), 0.5, 1, 2, 4, and 6 hours post dose
|
Cmax of capecitabine and its metabolites 5'deoxy-5-fluorocytidine (5'DFCR), 5'deoxy-5-fluorouridine (5'DFUR), and 5-fluorouracil.
|
0 (pre-dose), 0.5, 1, 2, 4, and 6 hours post dose
|
|
Time of maximum plasma concentration (Tmax) of capecitabine and metabolites
기간: 0 (pre-dose), 0.5, 1, 2, 4, and 6 hours post dose
|
Cmax of capecitabine and its metabolites 5'deoxy-5-fluorocytidine (5'DFCR), 5'deoxy-5-fluorouridine (5'DFUR), and 5-fluorouracil.
|
0 (pre-dose), 0.5, 1, 2, 4, and 6 hours post dose
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
협력자
협력자
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
연구 시작
2016년 5월 1일
기본 완료 (예상)
기본 완료
2018년 5월 1일
연구 완료 (예상)
연구 완료
2019년 11월 1일
연구 등록 날짜
최초 제출
최초 제출
2015년 8월 7일
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
2018년 3월 7일
처음 게시됨 (실제)
처음 게시됨
2018년 3월 14일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
2018년 3월 14일
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
2018년 3월 7일
마지막으로 확인됨
마지막으로 확인됨
2018년 3월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- SBRU201501
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
유방암에 대한 임상 시험
-
NCT03987217완전한피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8
-
NCT06216249모병전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8
-
NCT07468903모병전립선 선암종 | 2기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8
-
NCT04399824빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8
-
NCT04624256모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8
-
NCT06870396초대로 등록부신 종양 | 페로 크로 모세포종 및 paraganglioma (PPGL) | Adrenocorticol Cancer (ACC)
-
NCT05398302모병거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8
카페시타빈에 대한 임상 시험
-
NCT07019337아직 모집하지 않음전이성 유방암 | HER2 양성 유방암
-
NCT07051785아직 모집하지 않음